Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination.
The effects of verapamil and bendrofluazide used singly and in combination were examined in patients with primary hypertension in a patient blind, partly observer blind placebo controlled study of parallel group design; there were ten subjects in each arm of the trial. Verapamil 160 mg twice daily caused supine mean arterial pressure to fall by 21 mmHg; this reduction was significantly greater (p less than 0.05) than that induced by bendrofluazide 5 mg daily which caused a fall of only 10 mmHg. The addition of verapamil 160 mg twice daily to bendrofluazide 5 mg daily caused a further fall in pressure of 18 mmHg (p less than 0.005), but the reduction in pressure when bendrofluazide was added to verapamil was only 1 mmHg and not significant. Bendrofluazide therapy caused a fall in plasma potassium concentration and an increase in plasma urate concentration; urinary calcium excretion was reduced. Verapamil caused no detectable biochemical alterations in plasma or urine.
Benjamin
N
N
Department of Medicine, St. George's Hospital, London, U.K.
Phillips
R J
RJ
Robinson
B F
BF
D000328:Adult; D001539:Bendroflumethiazide / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004573:Electrolytes / Q000097:blood; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D004573:Electrolytes; D001539:Bendroflumethiazide; D014700:Verapamil